Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts
2020/02/04 by Haifa Kathrin Al‐Ali, Martin Grießhammer, Martin Griesshammer +21 · 26 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Myeloproliferative Neoplasms: Diagnosis and Treatment #Kruppel-like factors research #Eosinophilic Disorders and Syndromes
paper · pdf · doi:10.1111/bjh.16462
Abstract
Summary Ruxolitinib is a potent Janus kinase (JAK) 1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF). Ruxolitinib was assessed in JUMP, a large ( N = 2233), phase 3b, expanded‐access study in MF in countries without access to ruxolitinib outside a clinical trial, which included patients with low platelet counts (<100 × 10 9 /l) and patients without splenomegaly – populations that have not been extensively studied. The most common adverse events (AEs) were anaemia and thrombocytopenia, but they rarely led to discontinuation (overall, 5·4%; low‐platelet cohort, 12·3%). As expected, rates of worsening thrombocytopenia were higher in the low‐platelet cohort (all grades, 73·2% vs. 53·5% overall); rates of anaemia were similar (all grades, 52·9% vs. 59·5%). Non‐haematologic AEs, including infections, were mainly grade 1/2. Overall, ruxolitinib led to meaningful reductions in spleen length and symptoms, including in patients with low platelet counts, and symptom improvements in patients without splenomegaly. In this trial, the largest study of ruxolitinib in patients with MF to date, the safety profile was consistent with previous reports, with no new safety concerns identified. This study confirms findings from the COMFORT studies and supports the use of ruxolitinib in patients with platelet counts of 50–100 × 10 9 /l. (ClinicalTrials.gov identifier NCT01493414).
Cited by
- Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
- Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients. [europepmc]
- Management of myelofibrosis after ruxolitinib failure. [europepmc]
- Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. [europepmc]
- A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Ascending Dose and Food Effect Study to Evaluate the Tolerance, Pharmacokinetics of Jaktinib, a New Selective Janus Kinase Inhibitor in Healthy Chinese Volunteers. [europepmc]
- Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study. [europepmc]
- Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study. [europepmc]
- Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis. [europepmc]
- Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. [europepmc]
- From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox. [europepmc]
- Treatment Patterns, Health Care Resource Utilization, and Cost in Patients with Myelofibrosis in the United States. [europepmc]
- The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes. [europepmc]
- Trend of circulating CD34 + cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment. [europepmc]
- New approaches to tackle cytopenic myelofibrosis. [europepmc]
- Prediction of Survival and Prognosis Migration from Gold-Standard Scores in Myelofibrosis Patients Treated with Ruxolitinib Applying the RR6 Prognostic Model in a Monocentric Real-Life Setting. [europepmc]
- Efficacy and safety of ruxolitinib in patients with newly-diagnosed polycythemia vera: futility analysis of the RuxoBEAT clinical trial of the GSG-MPN study group. [europepmc]
- Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine. [europepmc]
- An improved reporter identifies ruxolitinib as a potent and cardioprotective CaMKII inhibitor. [europepmc]
- Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study. [europepmc]
- Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments. [europepmc]
- Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. [europepmc]
- Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial. [europepmc]
- Potential therapeutic targets of the JAK2/STAT3 signaling pathway in triple-negative breast cancer. [europepmc]
- Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. [europepmc]
- Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study. [europepmc]
- How I individualize selection of JAK inhibitors for patients with myelofibrosis. [europepmc]
Related